{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Pancreatic+Cancer+Stage+I",
    "query": {
      "condition": "Pancreatic Cancer Stage I"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 439,
    "total_pages": 44,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Pancreatic+Cancer+Stage+I&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-06-07T15:03:37.712Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01465659",
      "title": "Temozolomide and Pazopanib Hydrochloride in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors That Cannot Be Removed By Surgery",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Pancreatic Alpha Cell Carcinoma",
        "Pancreatic Beta Islet Cell Carcinoma",
        "Pancreatic Delta Cell Carcinoma",
        "Pancreatic G-cell Carcinoma",
        "Recurrent Islet Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "temozolomide",
          "type": "DRUG"
        },
        {
          "name": "pazopanib hydrochloride",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Northwestern University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 29,
      "start_date": "2011-12-12",
      "completion_date": "2021-01-27",
      "has_results": true,
      "last_update_posted_date": "2021-08-05",
      "last_synced_at": "2026-06-07T15:03:37.712Z",
      "location_count": 5,
      "location_summary": "Chicago, Illinois • Ann Arbor, Michigan • Philadelphia, Pennsylvania + 2 more",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01465659"
    },
    {
      "nct_id": "NCT06693986",
      "title": "Adenovirus (RGDCRAdCOX2F)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Adenocarcinoma of Pancreas"
      ],
      "interventions": [
        {
          "name": "Replicative Adenovirus Vector (RGDCRAdCOX2F)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Masonic Cancer Center, University of Minnesota",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 18,
      "start_date": "2024-12-27",
      "completion_date": "2029-10-15",
      "has_results": false,
      "last_update_posted_date": "2026-01-07",
      "last_synced_at": "2026-06-07T15:03:37.712Z",
      "location_count": 1,
      "location_summary": "Minneapolis, Minnesota",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06693986"
    },
    {
      "nct_id": "NCT01364805",
      "title": "New Treatment Option for Pancreatic Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Pancreatic Cancer"
      ],
      "interventions": [
        {
          "name": "Intravenous Vitamin C",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Jeanne Drisko, MD, CNS, FACN",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "21 Years and older"
      },
      "enrollment_count": 14,
      "start_date": "2011-04",
      "completion_date": "2015-10",
      "has_results": false,
      "last_update_posted_date": "2018-06-19",
      "last_synced_at": "2026-06-07T15:03:37.712Z",
      "location_count": 1,
      "location_summary": "Kansas City, Kansas",
      "locations": [
        {
          "city": "Kansas City",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01364805"
    },
    {
      "nct_id": "NCT04426669",
      "title": "A Study of Metastatic Gastrointestinal Cancers Treated With Tumor Infiltrating Lymphocytes in Which the Gene Encoding the Intracellular Immune Checkpoint CISH Is Inhibited Using CRISPR Genetic Engineering",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Gastrointestinal Epithelial Cancer",
        "Gastrointestinal Neoplasms",
        "Cancer of Gastrointestinal Tract",
        "Cancer, Gastrointestinal",
        "Gastrointestinal Cancer",
        "Colo-rectal Cancer",
        "Pancreatic Cancer",
        "Gall Bladder Cancer",
        "Colon Cancer",
        "Esophageal Cancer",
        "Stomach Cancer"
      ],
      "interventions": [
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Tumor-Infiltrating Lymphocytes (TIL)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Aldesleukin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Intima Bioscience, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 23,
      "start_date": "2020-05-15",
      "completion_date": "2026-01-22",
      "has_results": false,
      "last_update_posted_date": "2026-02-23",
      "last_synced_at": "2026-06-07T15:03:37.712Z",
      "location_count": 1,
      "location_summary": "Minneapolis, Minnesota",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04426669"
    },
    {
      "nct_id": "NCT00316420",
      "title": "Gemcitabine and Capecitabine in Patients With Advanced Pancreatic Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Pancreatic Cancer"
      ],
      "interventions": [
        {
          "name": "Capecitabine (Xeloda)",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Swedish Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2003-12",
      "completion_date": "2009-08",
      "has_results": false,
      "last_update_posted_date": "2010-03-08",
      "last_synced_at": "2026-06-07T15:03:37.712Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00316420"
    },
    {
      "nct_id": "NCT00739453",
      "title": "A Phase 1 Dose-escalation Study of OSI-906 and Erlotinib (Tarceva®)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Solid Tumors"
      ],
      "interventions": [
        {
          "name": "OSI-906",
          "type": "DRUG"
        },
        {
          "name": "erlotinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Astellas Pharma Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 95,
      "start_date": "2008-10-23",
      "completion_date": "2012-03-03",
      "has_results": false,
      "last_update_posted_date": "2024-11-20",
      "last_synced_at": "2026-06-07T15:03:37.712Z",
      "location_count": 3,
      "location_summary": "Aurora, Colorado • Baltimore, Maryland • Detroit, Michigan",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00739453"
    },
    {
      "nct_id": "NCT00707278",
      "title": "Radiation Therapy and Capecitabine/Oxaliplatin Chemotherapy in the Treatment of Locally Advanced Pancreas Adenocarcinoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Cancer",
        "Pancreas"
      ],
      "interventions": [
        {
          "name": "Radiation Therapy",
          "type": "RADIATION"
        },
        {
          "name": "Capecitabine",
          "type": "DRUG"
        },
        {
          "name": "Oxaliplatin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "RADIATION",
        "DRUG"
      ],
      "sponsor": "University of Utah",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 13,
      "start_date": "2005-09",
      "completion_date": "2011-08",
      "has_results": false,
      "last_update_posted_date": "2014-10-31",
      "last_synced_at": "2026-06-07T15:03:37.712Z",
      "location_count": 1,
      "location_summary": "Salt Lake City, Utah",
      "locations": [
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00707278"
    },
    {
      "nct_id": "NCT00096707",
      "title": "Dose Escalation Trial of 2-Deoxy-D-Glucose (2DG) in Subjects With Advanced Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Lung Cancer",
        "Breast Cancer",
        "Pancreatic Cancer",
        "Head and Neck Cancer",
        "Gastric Cancer"
      ],
      "interventions": [
        {
          "name": "2-deoxy-D-glucose (2DG)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Threshold Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 50,
      "start_date": "2004-02",
      "completion_date": "2008-07",
      "has_results": false,
      "last_update_posted_date": "2009-04-29",
      "last_synced_at": "2026-06-07T15:03:37.712Z",
      "location_count": 3,
      "location_summary": "Miami, Florida • Indianapolis, Indiana • San Antonio, Texas",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00096707"
    },
    {
      "nct_id": "NCT01852890",
      "title": "Gemcitabine, Ascorbate, Radiation Therapy for Pancreatic Cancer, Phase I",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Pancreatic Neoplasms"
      ],
      "interventions": [
        {
          "name": "Ascorbate",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        },
        {
          "name": "Radiation therapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "Joseph J. Cullen",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 16,
      "start_date": "2014-01",
      "completion_date": "2025-10-14",
      "has_results": false,
      "last_update_posted_date": "2025-10-24",
      "last_synced_at": "2026-06-07T15:03:37.712Z",
      "location_count": 1,
      "location_summary": "Iowa City, Iowa",
      "locations": [
        {
          "city": "Iowa City",
          "state": "Iowa"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01852890"
    },
    {
      "nct_id": "NCT01251640",
      "title": "Combination With Gemcitabine in Advanced Pancreatic Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Pancreatic Neoplasms"
      ],
      "interventions": [
        {
          "name": "BAY86-9766+Gemcitabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bayer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 90,
      "start_date": "2011-01-01",
      "completion_date": "2013-08-01",
      "has_results": false,
      "last_update_posted_date": "2021-04-08",
      "last_synced_at": "2026-06-07T15:03:37.712Z",
      "location_count": 2,
      "location_summary": "Aurora, Colorado • Pittsfield, Massachusetts",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Pittsfield",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01251640"
    }
  ]
}